CordovaCann Corp is a Canadian-domiciled company focused on building a diversified cannabis company... Show more
LVRLF moved above its 50-day moving average on August 12, 2025 date and that indicates a change from a downward trend to an upward trend. In of 59 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 15, 2025. You may want to consider a long position or call options on LVRLF as a result. In of 150 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LVRLF just turned positive on July 15, 2025. Looking at past instances where LVRLF's MACD turned positive, the stock continued to rise in of 72 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for LVRLF crossed bullishly above the 50-day moving average on August 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where LVRLF advanced for three days, in of 125 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 81 cases where LVRLF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The 50-day moving average for LVRLF moved below the 200-day moving average on July 15, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
LVRLF broke above its upper Bollinger Band on July 31, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LVRLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.657). P/E Ratio (0.000) is within average values for comparable stocks, (72.172). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.696). LVRLF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (0.652) is also within normal values, averaging (40.190).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LVRLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric